Credit Suisse’s Clovis Oncology, Inc. CLVS Stock Holding History

Credit Suisse’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,952	Closed	-$56K	–	4203
2022 Q3	$56K	Sell	46,952 -8	-0%	-$12	﹤0.01%	3523
2022 Q2	$85K	Sell	46,960 -101,754	-68%	-$150K	﹤0.01%	3566
2022 Q1	$301K	Buy	148,714 +21,673	+17%	+$42.6K	﹤0.01%	3229
2021 Q4	$343K	Buy	127,041 +7,210	+6%	+$26.7K	﹤0.01%	4058
2021 Q3	$536K	Buy	119,831 +8,746	+8%	+$42.1K	﹤0.01%	3763
2021 Q2	$643K	Sell	111,085 -18,206	-14%	-$107K	﹤0.01%	3679
2021 Q1	$907K	Sell	129,291 -290,897	-69%	-$1.95M	﹤0.01%	3389
2020 Q4	$2.02M	Sell	420,188 -31,112	-7%	-$157K	﹤0.01%	2810
2020 Q3	$2.63M	Sell	451,300 -66,024	-13%	-$395K	﹤0.01%	2215
2020 Q2	$3.49M	Buy	517,324 +367,887	+246%	+$2.79M	﹤0.01%	1946
2020 Q1	$951K	Sell	149,437 -28,619	-16%	-$230K	﹤0.01%	2683
2019 Q4	$1.86M	Buy	178,056 +13,922	+8%	+$101K	﹤0.01%	2655
2019 Q3	$646K	Sell	164,134 -80,941	-33%	-$655K	﹤0.01%	3287
2019 Q2	$3.64M	Buy	245,075 +85,981	+54%	+$1.55M	﹤0.01%	1998
2019 Q1	$3.95M	Sell	159,094 -17,778	-10%	-$446K	﹤0.01%	1901
2018 Q4	$3.18M	Sell	176,872 -78,073	-31%	-$1.6M	﹤0.01%	1914
2018 Q3	$7.49M	Buy	254,945 +99,939	+64%	+$3.87M	0.01%	1445
2018 Q2	$7.05M	Sell	155,006 -27,003	-15%	-$1.31M	0.01%	1479
2018 Q1	$9.61M	Buy	182,009 +88,558	+95%	+$5.17M	0.01%	1262
2017 Q4	$6.36M	Sell	93,451 -96,480	-51%	-$6.75M	0.01%	1598
2017 Q3	$15.7M	Buy	189,931 +29,278	+18%	+$2.32M	0.02%	977
2017 Q2	$15M	Sell	160,653 -103,156	-39%	-$6.31M	0.01%	957
2017 Q1	$16.8M	Buy	263,809 +128,821	+95%	+$7.83M	0.02%	923
2016 Q4	$6M	Sell	134,988 -253,590	-65%	-$8.93M	0.01%	1528
2016 Q3	$14M	Buy	388,578 +265,881	+217%	+$5.7M	0.01%	997
2016 Q2	$1.68M	Sell	122,697 -32,089	-21%	-$469K	﹤0.01%	2466
2016 Q1	$2.97M	Buy	154,786 +29,786	+24%	+$630K	﹤0.01%	1904
2015 Q4	$4.38M	Buy	125,000 +20,219	+19%	+$1.3M	0.01%	1691
2015 Q3	$9.63M	Sell	104,781 -35,646	-25%	-$3.08M	0.01%	1137
2015 Q2	$12.3M	Sell	140,427 -10,082	-7%	-$863K	0.01%	1111
2015 Q1	$11.2M	Buy	150,509 +20,976	+16%	+$1.48M	0.01%	1135
2014 Q4	$7.25M	Buy	129,533 +2,952	+2%	+$155K	0.01%	1491
2014 Q3	$5.74M	Buy	126,581 +3,563	+3%	+$149K	﹤0.01%	1649
2014 Q2	$5.09M	Buy	123,018 +50,729	+70%	+$2.61M	﹤0.01%	1950
2014 Q1	$5.01M	Buy	72,289 +635	+0.9%	+$46.6K	﹤0.01%	1759
2013 Q4	$4.32M	Sell	71,654 -1,597	-2%	-$86.9K	﹤0.01%	1973
2013 Q3	$4.45M	Buy	73,251 +60,120	+458%	+$4.26M	﹤0.01%	1739
2013 Q2	$879K	Buy	+13,131	New	+$590K	﹤0.01%	2894

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Credit Suisse's CLVS Position: Q4 2022 in Review

Credit Suisse sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 46,952 shares — an estimated $56K sold.

Credit Suisse first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $16.8M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Credit Suisse reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Credit Suisse sold 46,952 Clovis Oncology, Inc. shares in Q4 2022, an estimated $56K.
Credit Suisse first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
Credit Suisse's Clovis Oncology, Inc. position peaked at $16.8M in Q1 2017.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.